All posts by imreal

PetMeds® Signs Pet Insurance Partnership


News Image

“By giving our customers direct access to pet insurance, we will be able to greatly assist millions of pet parents in getting quality insurance that helps them care for their pets,” said Matt Hulett, CEO and President of PetMed Express.

PetMed Express, Inc. (PetMeds®, NASDAQ: PETS), Your Trusted Pet Health Expert™, today announced it will begin offering access to a high quality health and wellness insurance solution, Pumpkin Insurance Services Inc. (“Pumpkin”), to more than 2 million PetMeds customers.

Providing a quality accident and illness insurance solution is an important social issue because of the low participation rate of insured pets in the United States. The North American Pet Health Insurance Association estimates only 4.4 million pets were insured in 2021, less than 5% of the pet population.

“Today, there is a huge disconnect between the high penetration of pet ownership and the relatively low participation rate in insurance,” said Matt Hulett, CEO and President of PetMed Express. “By giving our customers direct access to pet insurance, we will be able to greatly assist millions of pet parents in getting quality insurance that helps them care for their pets.”

“Pumpkin’s goal has always been to positively impact the lives of millions of pets, pet parents, and veterinarians” said Alexandre Douzet, CEO of Pumpkin Pet Insurance. “Getting the PetMeds’ audience covered with a top-tier accident & illness insurance and optional, non-insurance wellness plan provided by Pumpkin, will drive more pets into veterinary clinics for regular preventive exams, diagnostic screenings, and best medicine.”

This offering is part of PetMeds’ larger “trusted pet health expert” strategy. It marks PetMeds’ third strategic initiative in the last 17 months, following the investment in Vetster in April 2022, which introduced a one-of-a-kind offering for pet parents in the pet telemedicine space. The second is the acquisition of PetCareRX which was recently announced in January 2023.

CapM Advisors acted as financial advisor to PetMeds in developing the strategic initiative.

##

ABOUT PETMEDS

Founded in 1996, PetMed Express is Your Most Trusted Pet Health Expert®, delivering prescription and non-prescription pet medications and other health products for dogs, cats, and horses at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and through its website at petmeds.com. PetMeds aims to be the most trusted pet health expert by providing incredible care and services that are affordable to the broadest group of pet parents because every pet deserves to live a long, happy, healthy life. For more information, please visit http://www.1800petmeds.com.

PETMEDS MEDIA CONTACT

Mary Eva Tredway

Butin PR

maryeva@butinpr.com

Share article on social media or email:

Revuud and Texas Hospital Association Partner to Revolutionize Healthcare IT Hiring


“We are thrilled to be working with THA and healthcare organizations in Texas to provide them with access to the best IT talent in the market,” said Eric Utzinger, CEO and Co-Founder of Revuud.

Revuud, a leading healthcare IT staffing marketplace, has joined forces with the Texas Hospital Association (THA) to change the game for healthcare organizations seeking top engineering talent. The dynamic duo is empowering a connected community of Healthcare Systems and highly qualified healthcare IT professionals to collaborate, without the need for a recruiter.

With the growing demand for skilled engineers in the healthcare industry, this partnership provides a much-needed solution that streamlines the hiring process, saves time, and offers access to a network of top IT talent. The platform provides healthcare organizations with the ability to quickly search and connect with IT candidates, review their portfolios, and evaluate their credentials and references, all in one place.

“We are thrilled to be working with THA and healthcare organizations in Texas to provide them with access to the best IT talent in the market,” said Eric Utzinger, CEO and Co-Founder of Revuud. “With this partnership, we are committed to making the hiring process faster, more efficient, and more effective for both healthcare systems and IT professionals.

“This strategic alliance brings numerous benefits to Texas healthcare organizations, including a wider pool of qualified IT candidates, reduced time to hire, and significantly lower hiring costs. IT professionals will also reap the rewards, with higher average pay, increased exposure to a wide range of healthcare organizations searching for top talent and a platform to showcase their skills and experience.

“Healthcare organizations in Texas are facing significant challenges when it comes to hiring top IT talent,” said Alex Huff, the VP of Health Technology Innovation for THA . “Our partnership with Revuud will help these organizations overcome these challenges and build a stronger, more effective IT team.

“With the new partnership in place, healthcare organizations in Texas can feel confident that they are working with a trusted partner to find the best IT talent for their needs, without the hassle and expense of traditional recruiting methods.

About Revuud

Revuud is a leading healthcare IT staffing marketplace that helps healthcare organizations connect with top engineering talent. Our mission is to revolutionize the way healthcare organizations hire IT talent by providing a faster, more efficient, and cost-effective solution. With our platform, healthcare organizations can easily search and connect with IT candidates, review their portfolios, and evaluate their credentials and references, all in one place. For more information, please visit http://www.revuud.com.

About THA

Founded in 1930, the Texas Hospital Association is the leadership organization and principal advocate for the state’s hospitals and health care systems. Based in Austin, THA enhances its members’ abilities to improve accessibility, quality and cost-effectiveness of health care for all Texans. One of the largest hospital associations in the country, THA represents 452 of the state’s non-federal general and specialty hospitals and health care systems, which employ some 400,000 health care professionals statewide. Learn more about THA at http://www.tha.org or follow THA on Twitter at http://twitter.com/texashospitals.

Share article on social media or email:



AZZLY® Partners with Zoom® to Provide Secure Telehealth Sessions Seamlessly From AZZLY Rize™ All-in-One Mental Health Platform


News Image

We are excited to provide Zoom as an integrated solution within our platform. The enhanced features and functionality is a plus for all telehealth providers and the patients that they serve. […] Keeping it easy to schedule, invite, remind, launch, join and bill made this an easy decision.

AZZLY, Inc., a leading behavioral and addiction treatment digital health solution, announced today that it has formed an Independent Software Vendor (ISV) Partnership with the leader in digital video conferencing solutions, Zoom.

As an all-in-one platform, AZZLY helps transform treatment centers to run more efficiently. Having Zoom virtual meetings available as a single sign on solution for all telehealth providers allows for appointment reminders, to record attendance, duration of sessions and no-shows, sharing of presentation material, educational links, group sessions, closed caption and more. Real time documentation means notes get completed timely for prompt reimbursement of services.

AZZLY Rize empowers your staff through its simplicity and automation. Key clinical and business features include e-check-in, scheduling, appointment reminder, EHR, telehealth, treatment plans, progress notes, outcome measurement tools, medication management, bed board, withdrawal management, e-prescribing, EPCS, PDMP, patient communication tools, reporting and electronic billing and claims submission.

As a true all-in-one addiction treatment and mental healthcare-specific electronic health record (EHR) and revenue cycle management (RCM) platform, improved compliance and accurate coding are achieved real-time. AZZLY proudly serves providers in over 31 states and is hosted in Microsoft Azure’s private cloud network. AZZLY serves the clinical and business needs of small, medium, and large organizations across all Levels of Care (LOC) and Programs offered.

“We are excited to provide Zoom as an integrated solution within our platform. The enhanced features and functionality is a plus for all telehealth providers and the patients that they serve.” said Coletta Dorado, Founder and CEO of AZZLY. “Almost everyone is familiar with Zoom, patients and providers, so keeping it easy to schedule, invite, remind, launch, join and bill made this an easy decision.”

March 9, 2023, AZZLY will host a webinar titled “Telehealth Models of Success”. The webinar is a panel-style discussion with experts in the field of mental healthcare and addiction treatment. Join us to learn how each of the panelists successfully utilized telehealth to expand their treatment programs. Register here: eventbrite.com/e/telehealth-models-of-success-tickets-537817876747.

Additionally, on March 16, 2023, another webinar will follow titled ”How to Use One Platform: AZZLY Rize™ + Zoom For Your Telehealth Model”. Attend to hear perspectives from both AZZLY and Zoom experts on the partnership and best practices for using telehealth within AZZLY’s all-in-one platform. Attendees will see a demonstration of the Zoom virtual capabilities within AZZLY Rize.. Register for either webinar at eventbrite.com/o/azzly-inc-60174844843 and follow AZZLY for updates on future webinars.

About AZZLY, Inc.:

Coletta Dorado founded AZZLY®, Inc. in 2009. Since 2014, AZZLY leadership has focused all resources on its behavioral healthcare platform, AZZLY Rize™, to meet the specific clinical and business needs of addiction treatment and mental healthcare organizations. AZZLY was recognized as a key player in the Global Patient Care Management Software industry (2020), on the Capterra® Shortlist™ for Mental Health Software (2021), a Software Advice ® Frontrunner™ for Mental Health Software (2021), and an honorable mention for the Healthiverse Heroes Awards™ by DrFirst® (2022). Email hello@azzly.com or visit azzly.com for more information.

Share article on social media or email:

Successful Approaches from Rare Disease and Cellular and Gene Therapy Product Approvals, Upcoming Webinar Hosted by Xtalks


A hub and spoke model for treating and referral sites allows efficient recruitment planning and wide patient study access, however, challenges the study execution with long-distance or cross-border patient management.

Clinical development is becoming increasingly complex with continuing innovations in cell and gene therapies, especially when factoring in the hurdles of rare disease research. To achieve cell and gene therapy approvals in rare diseases, it is essential to overcome challenges specific to these trials.

Common clinical challenges to consider when planning trials include the complexities related to gene therapy and underlying conditions, as well as needing to monitor patient visits closely and efficiently after administration to ensure study endpoint protection. Operational considerations are often associated with patient recruitment, retention, compliance and challenges behind long-term patient follow-up. A hub and spoke model for treating and referral sites allows efficient recruitment planning and wide patient study access, however, challenges the study execution with long-distance or cross-border patient management.

Additionally, the regulatory landscape continues to evolve to meet challenges with the ongoing development of innovative types of gene therapy, including gene editing, as well as the need for regulatory guidance and flexibility to ensure that a rare disease therapy’s development strategy will meet regulator expectations. Rare disease studies must consider the constraint of very low patient numbers while also needing to achieve appropriate statistical significance to demonstrate efficacy and meet regulatory expectations; having early and regular interactions with regulators to ensure agreement of proposed study designs is essential. Receiving Orphan Drug Designation for a product in development is an important milestone and provides numerous incentives, including regulatory assistance, which helps to facilitate interactions with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and other authorities from around the world.

Register now for the webinar on Rare Disease Day 2023 to join the discussion with Medpace medical, regulatory and operational experts on successful approaches for achieving cell and gene therapy approvals in rare diseases.

Join experts from Medpace, Terence Eagleton, MB BS, BSc, Senior Medical Director; Marco Tangelder, MD, PhD, Senior Medical Director; Laura Omoboni, MS, Executive Director, Clinical Trial Management; and Trevor Walker, DPhil, Senior Director, Regulatory Affairs, for the live webinar on Tuesday, February 28, 2023, at 1pm EST (10am PST).

For more information, or to register for this event, visit Successful Approaches from Rare Disease and Cellular and Gene Therapy Product Approvals.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Claire’s Place Foundation Executive Director to Speak at BreatheCon 2023


“I am honored to be a presenter at BreatheCon 2023,” said Claire’s Place Foundation Executive Director Melissa Yeager.

Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is pleased to announce that their Work Proudly Program will be featured at the Cystic Fibrosis Foundation’s BreatheCon 2023, February 23-25, 2023. Claire’s Place Foundation Executive Director Melissa Yeager will present the purpose and success of the Work Proudly Program at the virtual event.

The seventh annual BreatheCon, hosted by the Cystic Fibrosis Foundation, is a unique online event for adults with CF to safely gather virtually. The event is an inclusive space to participate in timely discussions, affinity groups, creative activities and more.

A recipient of the CF Foundation’s Impact Grant and Community Support Grant, the Claire’s Place Work Proudly Program was chosen to be featured in BreatheCon’s Community Program Showcase. The purpose of the Showcase is to highlight projects led by the CF community that support and empower people living with CF. The Claire’s Place presentation will be on February 23rd at 5:30 pm PST.

The Claire’s Place Work Proudly Program provides job training and equipment needed for work-from-home employment to adults with CF and caregivers. The program allows participants to gain the skills and access technology to be competitive in the job market and acquire flexible, work-from-home or hospital employment. Participants are recruited through a social worker referral.

“I am honored to be a presenter at BreatheCon 2023,” said Claire’s Place Foundation Executive Director Melissa Yeager. “We have been overwhelmed by the positive impact and demand for our Work Proudly Program since we launched it in 2020. I look forward to sharing success stories of our participants as well as answering questions and connecting with the BreatheCon attendees.”

If you are an adult with CF and would like to attend BreatheCon 2023 visit here to register.

About Claire’s Place Foundation, Inc.

Claire’s Place Foundation, Inc. is a 501(c)(3) non-profit organization providing support to children and families affected by cystic fibrosis (CF). Claire’s Place Foundation is named in honor of Claire Wineland who lived with CF her entire life and died at the age of 21. Claire was an activist, author, TEDx Speaker, social media star and received numerous awards. Claire’s foundation was a way for her to assure that others living with CF enjoyed the same hope, strength and joy that she enjoyed. Recipient of Los Angeles Business Journal’s “Small Nonprofit of the Year” and “Fundraiser of the Year” for its annual Glow Ride, the foundation provides grants to families affected by CF, offering both emotional and financial support. Today, Claire’s Place Foundation continues to carry on Claire’s legacy. For more information and make a donation, please visit http://www.clairesplacefoundation.org.

Share article on social media or email:

Global Clinical Sample Challenges — New Strategies for Molecular Testing & Flow Cytometry Panel Development, Upcoming Webinar Hosted by Xtalks


Each technology’s benefits and limitations must be considered along with the data that will be generated when deciding which is most appropriate for a specific molecular analysis.

Join this webinar to hear the featured speakers address global clinical sample challenges, with a focus on logistical considerations, new strategies for molecular testing, and flow cytometry panel development.

Clinical trials and investigational products are becoming more complex, such as within the field of cell and gene therapy, and so is the bioanalytical testing of patient samples. Such complex sample analysis plans necessitate diligent sample management and processing procedures, as well as careful selection of the most appropriate downstream testing methods and platforms especially considering that patient samples are limited. LabConnect’s sample processing, sample tracking and scientific support services work cross-functionally with partner labs around the world to ensure samples meet all testing requirements.

In clinical trials, flow cytometry analyses provide deep interrogation of cell populations. Therefore, it is critical to develop highly adaptable panels to meet the unique challenges of global trials. Highly flexible panels that consist of a validated backbone in multiple matrices and adaptable add-on packages to interrogate specific populations of interest are an efficient and cost-effective method that will provide quality, consistent and comparable reportable readouts across drug development programs.

Molecular testing is another powerful tool often utilized across many clinical sample types to help drive clinical research. While sample processing is important for these analyses, so too is selection of the downstream technology itself. Next-generation sequencing (NGS), RNA-sequencing (RNA-seq) using NGS, quantitative polymerase chain reaction (qPCR) and digital droplet PCR (ddPCR) are frequently used to evaluate impacts of investigational products and measure endpoints in clinical trials. Each technology’s benefits and limitations must be considered along with the data that will be generated when deciding which is most appropriate for a specific molecular analysis. LabConnect’s technical experts work with scientists at partner labs when evaluating approaches to ensure the needs of study sponsors are met.

Join experts from LabConnect, Joseph Marino, Sr Director, Scientific Operations; Dr. Loren Blake, MD, Study Director, Scientific Operations; and Rebecca McKee, Sr Scientific Project Manager, for the live webinar on Wednesday, March 1, 2023, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Global Clinical Sample Challenges — New Strategies for Molecular Testing & Flow Cytometry Panel Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

You Do Not Have to Make a Choice Between God and Science


News Image

This book shows that science and faith aren’t in mutual opposition, but highly complementary

Author James A. Cannon, Ph.D. explains the faith behind physics in Finding the Light: Science and its Vision ($15.99, paperback, 9781662865787; $29.99, dust jacket, 9781662865794; $7.99, e-book, 9781662865800).

Contrary to the popular belief that science opposes Christian faith, Cannon teaches that historical physical science, as well as modern physics, follow faith’s universal promptings within the human heart. He demonstrates how both have flourished together in the lives of prominent scientists throughout history, and argues that faith in God is a guardian of classical realism, the philosophical foundation of science.

This book shows that science and faith aren’t in mutual opposition, but highly complementary.

Dr. James A Cannon (b.1933 – d.2020), after serving in the US Navy during the Korean war, studied and practiced journalism as managing editor of the Fordham University newspaper. Then he switched his area of concentration to physics. He earned an MA at Columbia and a B.S. and Ph.D. at Fordham. He did basic research at Bell Labs, but having the heart of a teacher, he left to pursued a career spanning five decades as a revered professor of physics and chemistry at Pace University in New York. A neurological injury led to retirement. He suffered for a dozen years until complications from Parkinson’s and Covid-19 took his life. During this time, with of the able assistance of his devoted wife, Monica, Dr. Cannon wrote Finding the Light: Science and its Vision, a testament to his life’s work, his Catholic faith, his love of science and his love of teaching.

###

Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 15,000 titles published to date. Finding the Light is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.

Share article on social media or email:

Ideal Option Partners with Snohomish County and Others to Host Take Back and Recovery Event


Ideal Option, a national leader in outpatient medication-assisted treatment for opioids, methamphetamine, alcohol and polysubstance, is partnering with Holman Recovery Center, Snohomish County Health Department, Marysville Police Department, EvergreenHealth Monroe, Providence, Catholic Community Services, A1 Lifeline, Washington 2-1-1, and The Hand Up Project to help people in Marysville get started in recovery.

According to the Medical Examiner’s Office Drug Overdose Dashboard, in Snohomish County alone, there were 162 overdose deaths involving opioids in 2022, with 141 of those involving fentanyl.

Ideal Option data support the effectiveness of medication-assisted treatment for opioid use disorder. Among patients who remained in treatment with Ideal Option during 2021, urine drug testing shows 98% less fentanyl use and 93% less total opioid use.

Recovery Starts Today! will take place on Friday, February 24, 10 a.m. – 2 p.m. at the Ideal Option clinic in Marysville located at 1617 Grove St. Attendees can surrender illicit substances and paraphernalia for safe disposal, learn about community resources, complete intake and, if desired, see a provider immediately to start medication-assisted treatment. For nearly all patients, costs are covered by Medicaid or private insurance.

This event is designed to empower those in the community who are struggling with the disease of addiction to come forward without fear of legal repercussions and begin their recovery with medication-assisted treatment.

For questions about this event, email Senior Marketing Manager Olivia Roe at oliviaroe@idealoption.net.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 65,000 patients through a network of 84 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts all forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Constellation Health Services Celebrates 15th Anniversary


“At Constellation, everyone is family. We believe that and we go the extra mile, as anyone would for those they care for.” – Isaac Steg, CEO

In commemorating this milestone, the company will place special emphasis on the guiding principle of treating its staff, patients, and partners like family, with a tagline of “15 Years. 1 Family.”

“2023 will mark our fifteenth year in business in the Northeast, providing home health, hospice, personal care, ABA, and school-based therapy for tens of thousands of people who want the best services and support from the comfort of their home,” said Isaac Steg, CEO. “We’re incredibly proud of how far Constellation has come since 2008 and how many lives we’ve been able to impact. Our success ultimately comes down to how we support each other within the organization, and that feeds into how compassionately we care for our patients. At Constellation, everyone is family. We believe that and we go the extra mile, as anyone would for those they care for.”

The 15-year anniversary provides an opportunity for Constellation to celebrate its patients, employees, and healthcare partners. As a family-centered healthcare provider, creating a culture where everyone feels like family has been a focal point for the organization. Constellation credits its company culture for the reason they have strong relationships with patients and partners within the communities they serve. The company has a five-star rating for quality of care in New York state and has been recognized as a top workplace for several years.

Founded in 2008, Constellation is known for providing high-quality home health services through a complete continuum of care, surrounding its patients during various stages of life with care teams tailored to their needs and goals. Visit http://www.constellationhs.com to learn more.

Share article on social media or email:

Molecular Devices inks deal with HUB Organoids to advance automated intestinal organoid screening technology


News Image

Through this collaboration, we will enable the scale and reproducibility that drug hunters need to confidently participate in a new era of drug discovery and development.

Molecular Devices, LLC., a leading provider of high-performance life science solutions, and HUB Organoids (HUB), the pioneer in the field of adult stem cell-derived organoids, today announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

Under terms of the agreement, Molecular Devices will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types like heart and brain. The physiologically-relevant adult stem cell-derived organoids closely resembling human biology, will be used to demonstrate proof of concept for an end-to-end automated workflow that encompasses instrumentation and software analysis.

“Aligning with HUB Organoids supports our mission to fully automate complex protocols that increase efficiency and precision of biologically testing new therapeutics and future medications for patients,” said Susan Murphy, President of Molecular Devices. “HUB’s proven technology has been used to select drugs for Phase 1 clinical trials. Through this collaboration, we will enable the scale and reproducibility that drug hunters need to confidently participate in a new era of drug discovery and development.”

According to HUB, HUB Organoids® can speed up the drug development timeline to about five years, down from the industry’s expected 10- to 15-year bench-to-bedside window. Organoid applications coupled with innovative, automated solutions from Molecular Devices that culture, image, and analyze 3D models repeatably, give researchers an opportunity to screen with more physiologically relevant cell systems in a high-throughput manner to get drugs to market faster.

“With this new license deal, we are bringing together HUB´s world-leading organoid technology with Molecular Devices´ innovative, end-to-end workflow solutions, empowering scientists to increase the throughput for their experiments and tests,” said Bahar Ramezanpour, CBO at HUB. “We believe this partnership will enable scientists to achieve greater scale and reproducibility when working with patient-derived organoids.”

In 2022, the U.S. Senate unanimously passed the FDA Modernization Act 2.0 aimed at reducing animal testing in the drug discovery process. More physiologically relevant cell models like organoids have the potential to fill the gap as they better predict how a potential drug candidate will affect patients.

To learn more about Molecular Devices’ work advancing organoid research, click here.

About Molecular Devices

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe. Visit Molecular Devices at http://www.moleculardevices.com.

About HUB

HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoid. The technology invented by HUB’s scientists in the lab of world-renowned Prof. Hans Clevers represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology, provides drug screening services and access to its living organoid biobanks. Visit HUB at http://www.huborganoids.nl.

###

Share article on social media or email: